lpca Laboratories Ltd. has entered into Technology Transfer Agreement with Omexa Formulary Pvt. Ltd. for a biosimilar clone, process development and knowledge transfer for the global market.

This agreement shall enable Omexa to develop this anti-cancer biosimilar from early stage of development to clinical trials and subsequent commercial launch. This agreement will also strengthen Omexa's capability of biosimilar development.

Pranay Godha, Managing Director and CEO, lpca Laboratories said, "This collaboration with Omexa Formulary, an innovation driven and fast-growing biotech company, shall facilitate Omexa to build a solid foundation for potential anti-cancer and anti-inflammatory monoclonal antibody product development. This collaboration with Omexa in turn shall also help lpca in the development and delivery of affordable and quality biologic medication for the treatment of chronic illnesses in the global market - a presently unmet and crucial clinical need. lpca is committed to successfully develop quality and affordable biosimilars meeting global standards and gain a decisive edge in the battle against chronic ailments."

Dr. Nate Ramanathan, Managing Director & CEO, Omexa Formulary said, "This collaboration with lpca, a most reliable and trusted pharmaceutical company shall facilitate Omexa the availability of expertise and technology for the biosimilars development work and ensuring that Omexa play its part in serving our core values of affordable access to quality biologic drugs for a large population through our pioneering methods in R&D and manufacturing development."